Chimerix, Inc. (CMRX): Price and Financial Metrics
CMRX Price/Volume Stats
| Current price | $0.90 | 52-week high | $1.57 |
| Prev. close | $0.89 | 52-week low | $0.88 |
| Day low | $0.88 | Volume | 228,200 |
| Day high | $0.91 | Avg. volume | 391,152 |
| 50-day MA | $1.06 | Dividend yield | N/A |
| 200-day MA | $1.02 | Market Cap | 80.28M |
CMRX Stock Price Chart Interactive Chart >
Chimerix, Inc. (CMRX) Company Bio
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing novel, oral antivirals in areas of high unmet medical need. The company was founded in 2000 and is based in Durham, North Carolina.
Latest CMRX News From Around the Web
Below are the latest news stories about CHIMERIX INC that investors may wish to consider to help them evaluate CMRX as an investment opportunity.
Positive Signs As Multiple Insiders Buy Chimerix StockUsually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like... |
Chimerix Promotes Michelle LaSpaluto to Chief Financial OfficerProven Leader Brings More Than 25 Years of Financial ExperienceDURHAM, N.C., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the promotion of Michelle LaSpaluto, Vice President of Corporate Financial Planning and Investor Relations, to Chief Financial Officer effective December 1, 2023. “We are excited to announce this well |
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)DURHAM, N.C., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on November 20, 2023, the Compensation Committee of Chimerix’s Board of Directors granted an inducement award to a new employee of non-qualified stock options to purchase 150,000 shares of Chimerix’s common stock. The Compensation Committee of Chimerix’s Board of Directors approved the award as an inducement material to the new employee’s employment agreement in accordance with Nasdaq Listing rule 5635(c |
Chimerix Strengthens Executive Leadership Team with Appointment of Thomas Riga as Chief Operating and Commercial OfficerSeasoned Executive Brings More Than 25 Years of Industry Leadership Experience in Oncology Commercialization and Corporate Business DevelopmentDURHAM, N.C., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the appointment of Thomas Riga as Chief Operating and Commercial Officer. “We are excited to welcome Tom to the Chimerix |
Chimerix, Inc. (NASDAQ:CMRX) Q3 2023 Earnings Call TranscriptChimerix, Inc. (NASDAQ:CMRX) Q3 2023 Earnings Call Transcript November 2, 2023 Chimerix, Inc. misses on earnings expectations. Reported EPS is $-0.27 EPS, expectations were $-0.22. Operator: Good morning, ladies and gentlemen, and welcome to the Chimerix Third Quarter 2023 Earnings Conference Call. I would now like to introduce you to your host for today’s call, […] |
CMRX Price Returns
| 1-mo | N/A |
| 3-mo | -1.43% |
| 6-mo | -4.45% |
| 1-year | -22.41% |
| 3-year | -89.99% |
| 5-year | -66.67% |
| YTD | -6.49% |
| 2023 | -48.25% |
| 2022 | -71.07% |
| 2021 | 33.13% |
| 2020 | 137.93% |
| 2019 | -21.01% |
Continue Researching CMRX
Here are a few links from around the web to help you further your research on Chimerix Inc's stock as an investment opportunity:Chimerix Inc (CMRX) Stock Price | Nasdaq
Chimerix Inc (CMRX) Stock Quote, History and News - Yahoo Finance
Chimerix Inc (CMRX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...